Protease inhibitors and adverse birth outcomes: Is progesterone the missing piece to the puzzle?

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 4-7

  Powis, Kathleen M ^a,b   Shapiro, Roger L ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

HIV; pregnancy outcomes.; progesterone; protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; LAMIVUDINE; LOPINAVIR; PROGESTERONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

BOTSWANA; CD4+ T LYMPHOCYTE; DRUG MECHANISM; FEMALE; FETUS OUTCOME; GROWTH RETARDATION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MOUSE; NONHUMAN; NOTE; PERIPHERAL LYMPHOCYTE; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE LABOR; SMALL FOR DATE INFANT; STILLBIRTH; TH1 CELL; TH2 CELL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FETUS DEVELOPMENT; HIV INFECTIONS; INTRAUTERINE GROWTH RETARDATION; MALE; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

ANIMALS; FEMALE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGESTERONE;

EID: 84922439699     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu397     Document Type: Note

References (40)

1. Shapiro RL, Hughes M, Ogwu A, et al. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med 2010; 362:2282-94.
2. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-81.
3. de Vincenzi I, Farley T, Gaillard P, et al. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-80.
4. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28:483-7.
5. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-29.
6. SixWeek Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372: 300-13.
7. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection-recommendations for a public health approach. Geneva: World Health Organization, 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng. pdf. Accessed 28 June 2014.
8. European AIDS Clinical Society guidelines. Version 7.0. 2013. http://www.eacsociety. org/Portals/0/Guidelines-Online-131014. pdf. Accessed 29 June 2014.
9. AIDSinfo Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1- Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 29 June 2014.
10. British HIV Association guidelines for the management of HIV infection in pregnant women, 2012. 2014 interim review. http://www.bhiva.org/documents/Guidelines/Pregnancy/2012/BHIVA-Pregnancy-guidelinesupdate- 2014.pdf. Accessed 1 July 2014.
11. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIVinfected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66.
12. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705.
13. Powis KM, Smeaton L, Ogwu A, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr 2011; 56:131-8.
14. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57: 290-6.
15. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy in Abidjan, Cote dIvoire. AIDS 2008; 22: 1815-20.
16. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, The Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12:F241-7.
17. Townsend CL, Cortina-Borja M, PeckhamCS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-26.
18. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-14.
19. Short C-ES, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 2014; 15:233-8.
20. European Collaborative Study; Swiss Mother and Child HIV Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-20.
21. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of ritonavir boost? Clin Infect Dis 2012; 54:1348-60.
22. Cotter AM, Garcia AG, Duthely ML, Luke B, OSullivan MJ. Is Antiretroviral therapy during pregnancy associated with increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-201.
23. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105:836-48.
24. Taha TET, Dallabeta GA, Canner JK, et al. The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in Urban Malawi. Int J. Epidemiol 1995; 24:1022-9.
25. Braddick MR, Kreiss JK, Embree JE, et al. Impact of maternal HIV infection on obstetrical and early neonatal outcome. AIDS 1990; 4:1001-5.
26. Turner AN, Tabbah S, Mwapasa V, et al. Severity of maternal HIV-1 disease is associated with adverse birth outcomes in Malawian women. J Acquir Immune Defic Syndr 2001; 64:392-9.
27. Fiore S, Ferrazzi E, Newell M-L, Trabottoni D, Clerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis 2007; 195:914-6.
28. Shapiro RL, Souda S, Parekh N, et al. High prevalence of hypertension and placental insufficiency, butnoinuteroHIVtransmission, among women on HAART with stillbirths in botswana. PLoS One 2012; 7:e31580.
29. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152-54.
30. Powis KM, McElrath T, Hughes MD, et al. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana. J Acquir Immune Defic Syndr 2013; 62: 517-24.
31. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun 2010; 34:J287-99.
32. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55:386-93.
33. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011; 7:659-74.
34. Papp E, Mohammadi H, Loufty MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015; 211:10-8.
35. Fischbach FT, Dunning MB III. Manual of laboratory and diagnostic tests. 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2009.
36. Polgar B, Nagy E, Miko E, Varga P, Szekeres- Bartho J. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 2004; 71: 1699-705.
37. Salas SP, Marshall G, Gutierrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006; 47:203-8.
38. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production in lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009; 80:91-9.
39. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379-85.
40. Hudic I, Szekeres-Bartho J, Fatusic Z, et al. Dydrogesterone supplementation in women with threatened preterm delivery - the impact of cytokine profile, hormone profile, and progesterone-induced blocking factor. J Reprod Immunol 2011; 92:103-7.